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A B S T R A C T
Neuropeptide oxytocin (OT) is involved in the regulation of social and non-social behaviour. The central nucleus
of amygdala (CeA), part of the limbic system, plays an important role in learning, memory, anxiety and re-
inforcing mechanisms. CeA has been shown to be rich in OT receptors in rodents. Our previous findings indicated
that OT in the rat CeA has a dose dependent rewarding and anxiolytic effect. The aim of our present study was to
examine in the CeA the possible interaction of OT and D2 dopamine (DA) receptor antagonist Sulpiride on
reinforcement in place preference test and on anxiety in elevated plus maze test.
Wistar rats were microinjected bilaterally with 10 ng OT. In different group of animals 4 μg D2 DA receptor
antagonist was applied. Other animals received D2 DA receptor antagonist 15min before 10 ng OT treatment or
vehicle solution into the CeA. Rats receiving 10 ng OT spent significantly longer time in the treatment quadrant
during the test session in conditioned place preference test. Prior treatment with D2 DA receptor antagonist
blocked the rewarding effects of OT. Antagonist in itself did not influence the time rats spent in the treatment
quadrant. In elevated plus maze test, rats receiving 10 ng OT spent significantly longer time on the open arms.
Prior treatment with D2 DA receptor antagonist blocked the effects of OT.
Our results show that DA system plays a role in positive reinforcing and anxiolytic effects of OT because D2
DA receptor antagonist can block these actions.
1. Introduction
Nonapeptide oxytocin (OT) is widely distributed in the central
nervous system where it acts as a neurotransmitter and neuromodu-
lator. OT is mainly produced by the paraventricular, supraoptic and
accessory nuclei of the hypothalamus and it is released into numerous
brain regions including the central nucleus of amygdala (CeA) (Voorn
and Buijs, 1983; Knobloch et al., 2012; Grinevich et al., 2016). Besides
its peripheral effects (role in parturition and lactation), OT is well
known about its prosocial effects in mammals, including humans (Lee
et al., 2009; Grinevich et al., 2016). OT has been shown to regulate not
only the social behaviour such as affiliation, sexual behaviour, maternal
care, bonding, trust, social memory, social recognition, aggression but
also non-social behaviour, namely stress, anxiety, learning and memory
(Lee et al., 2009). OT can also promote anti-social behaviour by in-
creasing envy and gloating (Shamay-Tsoory et al., 2009). Furthermore,
OT is involved in pain perception and feeding behaviour as well (Lee
et al., 2009).
The CeA is part of the limbic system and receives dopaminergic fi-
bers from the mesolimbic dopaminergic system (MLDS). Amygdala
(AMY) plays an important role in the regulation of fear, anxiety, re-
inforcement, sexual behaviour and motivation. The CeA has been
shown to be relatively rich in oxytocin receptors (OTR) and receives
oxytocinergic fibers from hypothalamus (Voorn and Buijs, 1983;
Condeslara et al., 1994; Knobloch et al., 2012). OT has been demon-
strated to attenuate AMY responses in aversive situations (Sobota et al.,
2015) and modulates AMY reactivity to masked fearful eyes (Kanat
et al., 2015).
OT has been revealed to have rewarding properties in some mam-
malian brain structures (Liberzon et al., 1997; Dolen et al., 2013; Kent
et al., 2013; Song et al., 2016; Hung et al., 2017; Borland et al., 2018).
Namely, it has been shown that activation of OT receptors in the ventral
tegmental area is critical for the reinforcing properties of social inter-
actions (Borland et al., 2018). Peripherally administered OT has been
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shown to have motivational properties in conditioned place preference
test (Liberzon et al., 1997). Furthermore, Kent et al. have demonstrated
that OT induces conditioned place preference in female rats when in-
fused into lateral ventricle (Kent et al., 2013). The role of OT receptor
activation in social reward has been shown in the nucleus accumbens
and in ventral tegmental area using male mice and hamsters in the
experiments (Dolen et al., 2013; Song et al., 2016; Hung et al., 2017).
OT has been supposed to modify memory processes too (de Wied and
Versteeg, 1979; Gabor et al., 2012). However, it is also important to
note that intranasal OT administration does lead to conditioned social
place preference but not place preference in female mice (Kosaki and
Watanabe, 2016). Furthermore, it was also shown that potentiation in
OT activity during social reward attenuates or reverses the reinforcing
effects of drugs of abuse (Leong et al., 2018).
OT has been demonstrated to have anxiolytic effects (Bale et al.,
2001; Amico et al., 2004; Slattery and Neumann, 2010; Viviani et al.,
2011; Knobloch et al., 2012; de la Mora et al., 2016; Laszlo et al., 2016).
OT knock out mice show more anxious behaviour to stress (Amico et al.,
2004), meanwhile chronic i.c.v. administration of OT attenuates the
pathological high anxiety state of selectively bred Wistar rats (Slattery
and Neumann, 2010). Administration of OT into the CeA reveals an-
xiolytic effects in elevated plus maze test, open field test and reduced
freezing behaviour in fear conditioned rats (Bale et al., 2001; Viviani
et al., 2011; Knobloch et al., 2012; Laszlo et al., 2016). The anxiolytic
effects of OT is established inter alia through its interaction with me-
solimbic dopaminergic system (Baskerville and Douglas, 2008;
Rosenfeld et al., 2011; Love, 2013; de la Mora et al., 2016). MLDS has
been indicated to modulate amygdaloid anxiety (de la Mora et al.,
2010). Furthermore, it has been also shown that OT receptors and D2
DA receptors are co-localised within the CeA (Gimpl and Fahrenholz,
2001; Huber et al., 2005; de la Mora et al., 2012).
The goal of the present study was to investigate the possible effects
of OT and D2 DA receptor antagonist Sulpiride in the rat CeA on re-
inforcement in place preference test and on anxiety in elevated plus
maze test.
2. Materials and methods
2.1. Subjects
In our experiments, 68 adult male Wistar rats (36 rats were used in
conditioned place preference test and 32 rats were used in elevated plus
maze test) weighing 280–320 g at the beginning of the experiments
were housed individually and cared for in accordance with institutional
(BA02/2000–8/2012, BA02/2000–64/2017), national (Hungarian
Government Decree, 40/2013 (II. 14.)) and international standards
(European Community Council Directive, 86/609/EEC, 1986, 2010).
Rats were kept in a temperature- and light-controlled room (22 ± 2 °C;
12:12 h light–dark cycle with lights on at 6:00 a.m.). Standard labora-
tory food pellets (CRLT/N standard rodent food pellet, Charles River
Kft, Budapest, Hungary) and tap water were available ad libitum. All
behavioural tests were done during the rats' daylight period between
08:00 a.m. and 4:00 p.m.
2.2. Surgery
Rats were anesthetized i.p. by ketamine supplemented with dia-
zepam (Calypsol and Seduxen, Richter Gedeon, Hungary, ketamine:
80 mg/kg body weight, diazepam: 20mg/kg body weight). Animals
were stereotaxically implanted bilaterally with 22 gauge stainless steel
guide cannulae, directed toward and 1mm above the dorsal border of
the CeA (coordinates relative to bregma: AP:−2.3 mm, ML:± 4.1mm,
DV: −6.5mm) according to the rats' stereotaxic atlas (Paxinos GaW,
1986). Cannulae were fixed to the skull with three stainless steel screws
and dental acrylic. When not being used for injection, the guide can-
nulae were occluded with 27 gauge stainless steel obturators. Animals
were allowed a minimum of 6 days postoperative recovery before
starting the experiments, during which period they were handled daily.
2.3. Drugs and injection procedure
OT obtained from Sigma (Sigma-Aldrich Co., O6379) was bilaterally
microinjected. The applied dose was 10 ng (9.93 pmol) in 0.4 μl vo-
lume. OT was dissolved in 0.15M sterile saline solution containing
0.01M Na-acetate and 0.01M phosphate buffered saline (PBS, pH 7.4).
Control animals received this solution bilaterally as vehicle in equal
volume to that used for OT injections. D2 DA antagonist Sulpiride
[Sigma-Aldrich Co., S7771, 4 μg/0.4 μl] was diluted in 0.15M saline
solution containing 0.01M Na-acetate and 0.01M phosphate buffered
saline (PBS, pH 7.4). Four groups of animals were involved in the
conditioned place preference (CPP) experiment: Control group
(Veh+Veh) n=8; 10 ng OT treated group (Veh+ 10 ng OT) n=8;
10 ng OT pre-treated with D2 DA receptor antagonist group (D2 ANT +
OT) n=8; D2 DA receptor antagonist group (D2 ANT + Veh) n=8.
The antagonist or Veh treatments were applied 15min prior to OT or
Veh injections, respectively. The same drug treatments were applied in
both EPM experiment and CPP test, but in EPM 7–7 rats belonged to
each group. Solutions were kept in +4 °C before application. In this
article, all doses are reported as dose per side values. Drugs or vehicles
were bilaterally microinjected through a 30 gauge stainless steel in-
jection tube extending 1mm below the tips of the implanted guide
cannulae. The injection cannula was attached via polyethylene tubing
(PE-10) to a 10 μl Hamilton microsyringe (Hamilton Co., Bonaduz,
Switzerland). All injections were delivered by a syringe pump (Cole
Parmer, IITC, Life Sci. Instruments, California) in a 0.4 μl volume over a
60 s interval. After injection, cannulae were left in place for an addi-
tional 60 s to allow diffusion into the surrounding tissue. During the
injections rats were gently held in hand.
2.4. Conditioned place preference test (CPP)
Positive reinforcing effects of drugs can be measured by the CPP
(Tzschentke, 1998). Our corral apparatus consisted of a circular open
field with a diameter of 85 cm and 40 cm high wall. Black lines divided
the floor into four quadrants of equal size. External visual cues in the
surroundings guided the animals' spatial orientation inside the appa-
ratus (Hasenohrl et al., 1989). The room was dimly lit by 40 lx. The
place preference procedure consisted of one Habituation (day 1), two
Conditioning (day 2–3) and one Test (day 4) trials, each lasted for 900 s
(15min). The apparatus was cleaned and dried after each animal. All
trainings and tests were conducted in an isolated experimental room. In
the Habituation trial (day 1) animals were placed into the arena and
had free access to all parts of the apparatus for 900 s. The time the
animals spent in each of the four quadrants was measured. During
Conditioning trials (day 2–3) animals received the drug injections (see
in “Drugs and injection procedure”) and subsequently rats were re-
stricted to the treatment quadrant for 15min by means of a transparent
plexiglass barrier. Treatment quadrant was determined to be one of the
four quadrants in which the animal had spent neither the longest nor
the shortest time during habituation (Hasenohrl et al., 1989;
Zimmermann et al., 1999). Due to homogenous environment, there was
no initial quadrant preference. On the fourth day (Test trial) animals
had free access to all parts of the apparatus. The time that rats had spent
in each of the four quadrants was measured again. Behaviour of animals
was recorded by a video camera. Data were stored and motion analysis
was made by means of EthoVision Basic software (Noldus Information
Technology B.V., Wageningen, The Netherlands). The number of entries
into the four quadrants was also recorded during Habituation and Test
trials, as a measure of gross locomotor activity. In order to measure
acute effects of OT on spontaneous behaviour, frequency of rearing and
grooming were also analysed.
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2.5. Elevated plus maze test (EPM)
Anxiety was evaluated in the EPM test. The apparatus was con-
structed of gray coloured wooden planks consisting of two opposite
open arms (50× 10cm) and two opposite enclosed arms
(50× 10×40cm) with an open roof. The maze was elevated to a
height of 100 cm above the floor. After drug administrations the ani-
mals were placed into the centre of the maze (central platform), facing
one of the enclosed arms. The trials lasted 5min during which the
number of entries into each arm, and the time spent on the open and
enclosed arms were recorded. Each rat was tested only once. Data were
stored and motion analysis was made by means of EthoVision Basic
software.
2.6. Histology
At the end of experiments, rats received an overdose of Calypsol and
Seduxen mixed in the ratio of 4:1 and were transcardially perfused with
isotonic saline followed by 10% formalin solution. After 1 week of
postfixation, brains were frozen, cut into 40 μm serial sections and
stained with Cresyl-violet. Injection sites were reconstructed according
to the stereotaxic atlas of the rat brain (Paxinos GaW, 1986). Only data
from rats with correctly placed cannulae were analysed.
2.7. Statistical analysis
Data are presented as mean ± standard error of the mean (S.E.M.).
One-way and mixed ANOVAs followed by Tukey's post hoc analysis and
effect size estimation (eta squared for ANOVAs and Cohen's d for pair-
wise comparisons) were employed. Statistical significance was estab-
lished at p < 0.05 (IBM SPSS Statistics 26).
3. Results
3.1. Histology
Histological examination showed that in 60 cases of 68 animals, the
cannulae were precisely and symmetrically located in the target area
(CeA). The tracks of cannulae and tip positions were determined by
evidence of debris and moderate glial proliferation. Schematic illus-
tration of cannula placements is shown in Fig. 1.
The eight rats with misplaced injection sites were excluded from
subsequent analysis (Fig. 1 B.). Among these rats, in 3 cases, the can-
nula tips were symmetrically entered into the liquor space at the basis
of the brain. In 2 cases cannula tips were symmetrically located 1mm
below the target area, hence bilateral injections were made in the ba-
somedial AMY. In 2 cases cannula tips were located laterally or medi-
ally and 1mm above the AMY, thus injections were made in the cau-
date-putamen on one side and in the internal capsule on the other side.
In 1 case cannula tips were placed laterally or medially to the target
area, therefore injections were made in the lateral and basolateral AMY
or in the medial AMY nucleus. Behavioural data concerning these in-
correct and diverse placements were not enough to draw far-reaching
conclusions.
3.2. Conditioned place preference test
3.2.1. D2 DA receptor antagonist +OT treatment
Our previous data showed that OT has positive reinforcing proper-
ties when microinjected into the rat CeA (Laszlo et al., 2016). According
to our hypothesis, these effects may be mediated via the modulation of
the MLDS. Therefore, we examined whether the positive reinforcing
effects of OT can be attenuated by blocking the D2 DA receptors. The
effects of intraamygdaloid D2 DA antagonist pre-treatment on time
spent in the treatment quadrant during CPP is shown in Fig. 2. Mixed
ANOVA analysis revealed significant effect on trials [F(3,32)= 4.035,
p < 0.05] and there was a significant effect of treatment [F
(1,32)= 11.200, p < 0.01] along with the significance in the inter-
action of treatment and trials [F(3,32)= 11.972, p < 0.01]. The 10 ng
OT increased the time animals spent in the treatment quadrant during
Test session compared to the Control group (p < 0.05, η2= 0.654,
d=−2.572) and compared to that of during Habituation (p < 0.05,
η2= 0.750, d=−3.237). When D2 DA antagonist Sulpiride was ad-
ministered prior to 10 ng OT treatment, it blocked the positive re-
inforcing effect (p < 0.05, η2= 0.520, d=−1.947). Sulpiride ad-
ministered alone (n=8) failed to have any effect on place preference
behaviour on its own: time spent in the treatment quadrant during Test
session did not differ from that of Control animals but significantly
differed from the 10 ng OT treated group (p < 0.05, η2= 0.493,
d=−1.845).
The gross locomotor activity (distance moved in cm) of the rats was
measured during the entire experiment. The subjects were in drug free
state during the Habituation and Test trials and there was no significant
difference among the different groups, as well as Habituation vs Test
trials did not show significant difference as far as the covered distance is
concerned (Table 1). During the Conditioning trials, when the animals
received the drug injections and right after rats were restricted into a
treatment quadrant, there were no statistical differences regarding lo-
comotor activities (Table 1), rearing and freezing (data are not shown).
Animals covered shorter distance during the Conditioning trials than in
Habituation and Test trials because they were restricted into a treat-
ment quadrant (Table 1). There were no statistical differences among
the groups, when total number of entries into the treatment quadrant
was measured during the Habituation trials and Test trials, respectively
(data are not shown).
3.3. Elevated plus maze test
Our previous data showed that OT has anxiolytic effects when mi-
croinjected into the rat CeA (Laszlo et al., 2016). According to our
hypothesis, these effects may be mediated via the modulation of the
MLDS. Therefore, we examined whether the anxiolytic effects of OT can
be attenuated by blocking the D2 DA receptors. The effects of in-
traamygdaloid D2 DA antagonist pre-treatment on time spent in the
open arms during EPM is shown in Fig. 3. Based on the one way ANOVA
analysis there was a significant effect among the groups [F(3,
24)= 7.851, p < 0.01, η2= 0.495]. Tukey post hoc test revealed that
10 ng OT treated rats (n=7) spent significantly more time in the open
arms compared to Control group, (n=7, p < 0.05, d=−2.03) or D2
DA antagonist pre-treated group (D2 ANT + OT) (n=7, p < 0.05,
d=−1.502) or D2 DA antagonist treated group (D2 ANT) (n=7,
p < 0.05, d=−2.122). The D2 DA antagonist pre-treatment pre-
vented the anxiolytic effect of 10 ng OT. The D2 DA antagonist in itself
did not influence the time spent in open arms. There was no statistical
difference among the Control, D2 DA antagonist treated (D2 ANT) and
D2 DA antagonist +10 ng OT (D2 ANT+OT) treated group as far as the
time spent in the open arms is concerned.
The locomotor activity (distance moved in cm) of the rats was
measured during the EPM test. There were no statistical differences
regarding locomotor activities (Table 2).
4. Discussion
Our previous data demonstrated that 10 ng OT has positive re-
inforcing effects in place preference test and anxiolytic effects in ele-
vated plus maze test when microinjected in the rat CeA (Laszlo et al.,
2016). Despite the limitations of our study (only male Wistar rats were
used and after their surgery they were kept in individual cages), our
present results show that the rewarding and anxiolytic effects of OT can
be eliminated by using D2 DA antagonist (Sulpiride) pre-treatment. The
interaction between oxytocinergic and dopaminergic system has been
already indicated in some aspects (Rosenfeld et al., 2011; Love et al.,
K. László, et al. Hormones and Behavior 124 (2020) 104777
3
2012; Love, 2013). OT receptors have been shown to co-localize with
D2 DA receptors within the CeA, ventral and dorsal striatum (Gimpl and
Fahrenholz, 2001; Huber et al., 2005; Romero-Fernandez et al., 2013).
OT receptors have been demonstrated to be present on dopaminergic
neurons of the ventral tegmental area that project to the limbic region
(Peris et al., 2017). Furthermore, OT has been shown to significantly
increase the potency of D2 DA receptor agonist quinpirole to block the
activity of AC-PKA-CREB pathway (de la Mora et al., 2016). Moreover,
it has been demonstrated that mesolimbic DA release is modified by
systemic administration of OT in mice (Estes et al., 2019).
The role of DA in reinforcement has long been suggested (Self and
Stein, 1992; Abrahams et al., 1998; Bardo et al., 1999; Sinnott et al.,
1999; Liao, 2008; Baracz and Cornish, 2013; Haghparast et al., 2013).
Studies showed that self-administration and conditioned place
preference can be established by DA receptor agonists, furthermore
amphetamine, cocaine, morphine induced place preference can be at-
tenuated by DA receptor antagonists (Self and Stein, 1992, Abrahams
et al., 1998, Bardo et al., 1999, Sinnott et al., 1999, Liao, 2008, Baracz
and Cornish, 2013, Haghparast et al., 2013). Nevertheless, D1 and D2
DA agonist microinjected into CeA were not rewarding, moreover D1
and D2 DA antagonist, in accordance with our present findings, could
not induce place-aversion when microinjected into the CeA (Rezayof
et al., 2002; Zarrindast et al., 2003). Our present results and data of the
literature indicate that the inhibition of D2 DA receptors does not have
significant effect on locomotor behaviour and on motivation of the
animals when applied alone, without the stimulation of the OT re-
ceptors (Zarrindast et al., 2011). However, our data show that DA D2
receptor antagonist can block the positive reinforcing effects of OT
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Fig. 1. Illustration of reconstructed injection sites. Correct bilateral injection placements are indicated as closed, gray and black circles in the CeA on panel A
(n=60). Incorrect injection placements are indicated on panel B (n=8). Brain structure diagrams of coronal sections are adapted from the stereotaxic atlas of
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Fig. 2. Effects of D2 DA antagonist pre-treatment in
the CeA on conditioned place preference induced by
OT. Columns represent mean time spent in the
treatment quadrant (± S.E.M.) during Habituation
and Test sessions, respectively. Control: vehicle
treated rats (n=8), 10 ng OT: animals microinjected
with 10 ng OT (n= 8), D2 ANT + OT: animals mi-
croinjected with 10 ng OT pre-treated with 4 μg
Sulpiride (n=8), D2 ANT: rats treated with 4 μg
Sulpiride (n=8). ٭ p < 0.05, for more explanation
see the text.
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when microinjected into CeA. In addition to our results, inhibition of
the D2 DA or D1 DA receptors of the CeA attenuates place preference
induced by morphine. Furthermore, stimulation of intraamygdaloid D2
DA or D1 DA receptors promotes the positive reinforcing effects of
morphine (Rezayof et al., 2002, Zarrindast et al., 2003). Based on the
aforementioned, it can be assumed that DA receptors of the CeA might
be involved in memory consolidation rather than directly modulating
motivational processes. Namely, OT induced positive motivational ef-
fects could be associated with the treatment quadrant temporarily,
which might be equivalent with the formation of short-term memory.
The established short-term memory might deteriorate over time but DA
receptor agonists might strengthen this memory trace, developing a
stronger place preference compared to the controls. Furthermore,
consolidation of the short-term memory can be inhibited by DA re-
ceptor antagonists when microinjected into the rat CeA, which leads to
lessening of place preference (Rezayof et al., 2002; Zarrindast et al.,
2003; Lenard et al., 2017). There are limitations of the aforementioned
theory. Namely, it is difficult to distinguish between memory related
and motivational aspects of the CPP. However, test trial depends on
whether the animals remember the respective association, which is
considered to be a result of learning and memory and observed as CPP
(Huston et al., 2013). The possible role of intraamygdaloid DA re-
ceptors in memory consolidation is supported by other publications as
well. It has been revealed that the indirect DA agonist amphetamine,
which is a well-known reinforcer, enhances memory consolidation in
Pavlovian learning and cued version of Morris water maze test (Packard
et al., 1994). The activation of the D3 DA receptors, which belong to the
D2 DA receptor family, facilitates memory consolidation in dis-
criminative Pavlovian learning in the CeA, but not in the basolateral
AMY (Hitchcott and Phillips, 1998). Unfortunately, there is no direct
evidence so far demonstrating the role of CeA D2 DA receptors in the
modulation of synaptic plasticity.
It is known that AMY has principal role in the modulation of anxiety
and fear. It has been revealed that the CeA plays an outstanding role
both in the regulation of unconditioned and conditioned fear responses
(Ciocchi et al., 2010). It is also known that OT is an important mod-
ulator of anxiety in the AMY (Condeslara et al., 1994; Bale et al., 2001;
Knobloch et al., 2012; Laszlo et al., 2016). OT can supress the activity of
CeA neurons which project to the lateral hypothalamus and brain stem
nuclei, which play a role in expression of fear response (Viviani et al.,
2011). Furthermore, it has been demonstrated that AMY is innervated
by MLDS (de la Mora et al., 2010). Studies show the involvement of
MLDS in amygdaloid anxiety related behaviour (Guarraci et al., 2000,
de la Mora et al., 2008, de la Mora et al., 2010, de la Mora et al., 2012).
It has been shown that D2 DA receptor expressing CeA neurons estab-
lish a pathway for suppressing appetitive behaviours (Kim et al., 2017).
Thus, being inhibitory, D2 DA receptors can inhibit the activity of this
‘aversive’ pathway. However, controversial data surround the effects of
D2 DA receptor antagonist on anxiety in case of CeA application
(Guarraci et al., 2000; de la Mora et al., 2012). On one hand, D2 DA
antagonist Raclopride has been demonstrated to have anxiogenic effects
(de la Mora et al., 2012). Namely, de la Mora et al. showed that Ra-
clopride increases burying behaviour in the Shock-Probe Burying when
microinjected into the CeA (de la Mora et al., 2012). On the other hand,
D2 DA receptor antagonist (Eticlopride) treated animals showed an-
xiolytic like behaviour after CeA application (Guarraci et al., 2000).
Table 1
Distance covered during the CPP trials (± S.E.M.) Control: vehicle treated rats (n= 8), 10 ng OT: animals microinjected with 10 ng OT (n=8), DA D2 antagonist:
rats treated with 4 μg Sulpiride (n=8), DA D2 antagonist + OT: animals microinjected with 10 ng OT pre-treated with 4 μg sulpiride (n= 8), for more explanation
see the text.
Distance covered (cm/15min)
(avg ± SEM)
Habituation avg. of conditioning trials Test
control (n=8) 6389.12 ± 553.85 3407.33 ± 252.52 5845.16 ± 509.95
10 ng OT (n= 8) 6278.25 ± 422.35 3335.40 ± 301.18 5975.00 ± 511.11
DA D2 antagonist (n=8) 6538.15 ± 548.55 2995.88 ± 269.56 5593.78 ± 505.50
DA D2 antagonist+OT (n=8) 6848.05 ± 323.45 3075.30 ± 273.25 5960.66 ± 392.04
           Test
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Fig. 3. Effects of D2 DA antagonist pre-treatment in
the CeA in elevated plus maze (EPM) test. Columns
represent mean time (± S.E.M.) spent in the open
arms. Control: vehicle treated rats (n=7), 10 ng OT:
animals microinjected with 10 ng OT (n= 7), D2
ANT+OT: animals microinjected with 4 μg Sulpiride
and 10 ng OT (n=7) D2 ANT: animals microinjected
with 4 μg Sulpiride (n=7). ٭ p < 0.05, for more
explanation see the text.
Table 2
Distance covered during the EPM test (± S.E.M.). Control: vehicle treated
rats (n=7), 10 ng OT: animals microinjected with 10 ng OT (n=7), DA D2
antagonist: rats treated with 4 μg Sulpiride (n= 7), DA D2 antagonist +
OT: animals microinjected with 10 ng OT pre-treated with 4 μg Sulpiride
(n=7), for more explanation see the text.
distance covered (cm/5min)
(avg ± SEM)
EPM test
control (n=7) 1397.25 ± 93.66
10 ng OT (n= 7) 1448.41 ± 101.08
DA D2 antagonist (n= 7) 1338.98 ± 108.01
DA D2 antagonist+OT (n=7) 1321.50 ± 103.12
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Namely, Guarracci et al. demonstrated that Eticlopride blocks condi-
tioned freezing (Guarraci et al., 2000). In our experiments, D2 DA an-
tagonist Sulpiride showed neither anxiolytic nor anxiogenic properties
when microinjected alone to the rat CeA but it could block the anxio-
lytic effects of OT. What can be the explanation for this apparent con-
tradiction? One may suppose that the endogenous DA levels were dif-
ferent in the above mentioned experiments that could affect the
anxiety. Indeed, it has been demonstrated that in the CeA there is a rest
tonic DA level (Young and Rees, 1998). Based on this finding it can be
assumed that the anxiolytic or even anxiogenic effect of the D2 DA
antagonist depends on the actual environmental and homeostatic con-
ditions of the animal (e.g. the applied behavioural test) which can be
reflected by the intra-CeA DA level. It has been also demonstrated that
OT receptor - D2 DA receptor heterocomplexes exist in the CeA and D2
DA receptor agonist Quinpirole can enhance the OT induced increases
in the activity of the PLCbeta-IP3-calcineurin and RAS-MAPK-pELK
cascade (de la Mora et al., 2016). According to our assumptions, D2 DA
receptor antagonist blocks the anxiolytic effects of OT via inhibiting OT
receptor - D2 DA receptor heterocomplexes. Taken together the above
mentioned data, it is presumptive that OT interacts with dopaminergic
system to yield its anxiolytic and positive reinforcing effects.
Moreover, our data suggest that both the OT and D2 DA receptor
activations are necessary for the development of the place preference
and anxiolytic effects. Since exogenous DA or its agonist were not ap-
plied in our experiment, therefore likely the endogenous intra-CeA DA
levels ensures the appropriate D2 DA receptor activation, which can be
eliminated by intra-CeA Sulpiride administration.
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